The Centers for Medicare & Medicaid Services announced the selection of 15 additional drugs covered in Medicare Part D under the Medicare Drug Price Negotiation Program of the Inflation Reduction Act. Negotiations with participating drug companies for these 15 drugs will occur in 2025 and any negotiated prices will become effective in 2027.
The 15 drugs are the following: 1) Ozempic, Rybelsus, Wegovy; 2) Trelegy Ellipta; 3) Xtandi; 4) Pomalyst; 5) Ibrance; 6) Ofev; 7) Linzess; 8) Calquence; 9) Austedo, Austedo XR; 10) Breo Ellipta; 11) Tradjenta; 12) Xifaxan; 13) Vraylar; 14) Janumet, Janumet XR; and 15) Otezla. For details on utilization rates and indications of these drugs, see CMS' fact sheet here.
CMS stated that between November 2023 and October 2024, about 5.3 million people with Medicare Part D coverage used these drugs, accounting for about $41 billion in total gross covered prescription drug costs under Medicare Part D, or about 14 percent, during that time.
NCPA continues to advocate on behalf of community pharmacy to CMS over reimbursement and administrative concerns with the MDPN program. To see our talking points on the MDPN program, click here. For resources on the Inflation Reduction Act, click here.
